Clinical Trial Update: Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating bemarituzumab in combination with FLOT chemotherapy for perioperative treatment of FGFR2b-overexpressing gastric/GEJ adenocarcinoma h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Bemarituzumab (bemarituzumab)
• DOCETAXEL (DOCETAXEL)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Institut Cancerologie de l'Ouest | Conditions: Gastric and Gastro-oesophageal Junction (GEJ) Adenocarcinomas, Overexpression FGFR2b | Phase 2 | Status: WITHDRAWN